tiprankstipranks
Trending News
More News >
Sino Biopharmaceutical Ltd (HK:1177)
:1177
Hong Kong Market

Sino Biopharmaceutical (1177) Ratios

Compare
12 Followers

Sino Biopharmaceutical Ratios

HK:1177's free cash flow for Q4 2024 was ¥0.81. For the 2024 fiscal year, HK:1177's free cash flow was decreased by ¥ and operating cash flow was ¥0.13. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
1.26 1.05 1.29 1.53 2.08
Quick Ratio
1.14 0.96 1.17 1.41 1.91
Cash Ratio
0.49 0.42 0.43 0.63 0.97
Solvency Ratio
0.20 0.13 0.23 0.68 0.24
Operating Cash Flow Ratio
0.00 0.27 0.31 0.35 0.49
Short-Term Operating Cash Flow Coverage
0.00 0.54 0.64 0.81 3.43
Net Current Asset Value
¥ 2.05B¥ -1.63B¥ -185.83M¥ 688.86M¥ -2.00B
Leverage Ratios
Debt-to-Assets Ratio
0.15 0.20 0.22 0.20 0.30
Debt-to-Equity Ratio
0.31 0.41 0.47 0.40 0.85
Debt-to-Capital Ratio
0.23 0.29 0.32 0.29 0.46
Long-Term Debt-to-Capital Ratio
0.06 0.03 0.12 0.15 0.42
Financial Leverage Ratio
2.05 2.09 2.15 2.00 2.82
Debt Service Coverage Ratio
0.73 0.53 0.58 2.57 3.13
Interest Coverage Ratio
0.00 11.68 15.24 61.11 15.12
Debt to Market Cap
0.10 0.17 0.18 0.14 0.12
Interest Debt Per Share
0.29 0.56 0.77 0.66 0.77
Net Debt to EBITDA
0.04 0.45 0.80 0.13 0.55
Profitability Margins
Gross Profit Margin
81.51%80.95%79.86%80.15%78.08%
EBIT Margin
17.91%22.54%19.61%70.29%22.57%
EBITDA Margin
21.16%26.64%23.25%73.99%27.67%
Operating Profit Margin
21.76%22.08%23.25%70.21%20.67%
Pretax Profit Margin
18.28%20.65%20.08%69.14%21.20%
Net Profit Margin
12.12%8.90%17.38%54.38%18.36%
Continuous Operations Profit Margin
16.57%17.61%15.70%61.85%18.36%
Net Income Per EBT
66.32%43.10%86.57%78.66%86.59%
EBT Per EBIT
84.02%93.50%86.37%98.47%102.55%
Return on Assets (ROA)
5.35%3.67%7.81%24.13%9.19%
Return on Equity (ROE)
10.95%7.65%16.82%48.23%25.92%
Return on Capital Employed (ROCE)
13.70%14.11%15.24%41.73%13.48%
Return on Invested Capital (ROIC)
10.63%9.45%10.77%32.50%11.18%
Return on Tangible Assets
5.61%3.72%8.05%24.83%9.65%
Earnings Yield
3.49%3.28%6.66%17.50%3.66%
Efficiency Ratios
Receivables Turnover
5.81 5.70 6.20 6.27 8.11
Payables Turnover
3.56 3.74 3.08 2.97 2.66
Inventory Turnover
2.25 2.50 2.49 2.75 2.76
Fixed Asset Turnover
2.81 2.64 3.11 3.15 3.30
Asset Turnover
0.44 0.41 0.45 0.44 0.50
Working Capital Turnover Ratio
9.12 7.50 4.13 2.68 1.65
Cash Conversion Cycle
122.71 112.22 86.92 68.02 40.21
Days of Sales Outstanding
62.81 64.03 58.89 58.23 44.98
Days of Inventory Outstanding
162.32 145.82 146.67 132.64 132.42
Days of Payables Outstanding
102.43 97.63 118.64 122.85 137.19
Operating Cycle
225.14 209.85 205.56 190.87 177.39
Cash Flow Ratios
Operating Cash Flow Per Share
0.00 0.26 0.34 0.29 0.28
Free Cash Flow Per Share
0.00 0.19 0.24 0.19 0.18
CapEx Per Share
0.00 0.07 0.09 0.10 0.10
Free Cash Flow to Operating Cash Flow
0.00 0.72 0.73 0.65 0.65
Dividend Paid and CapEx Coverage Ratio
0.00 2.60 2.11 1.89 1.75
Capital Expenditure Coverage Ratio
0.00 3.56 3.67 2.83 2.86
Operating Cash Flow Coverage Ratio
0.00 0.48 0.45 0.44 0.37
Operating Cash Flow to Sales Ratio
0.00 0.23 0.22 0.20 0.23
Free Cash Flow Yield
0.00%6.14%6.07%4.16%2.92%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
28.65 30.45 15.02 5.71 27.33
Price-to-Sales (P/S) Ratio
3.47 2.71 2.61 3.11 5.02
Price-to-Book (P/B) Ratio
3.14 2.33 2.53 2.76 7.08
Price-to-Free Cash Flow (P/FCF) Ratio
0.00 16.28 16.48 24.04 34.22
Price-to-Operating Cash Flow Ratio
0.00 11.71 11.99 15.55 22.28
Price-to-Earnings Growth (PEG) Ratio
1.08 -0.43 -0.23 0.02 -3.42
Price-to-Fair Value
3.14 2.33 2.53 2.76 7.08
Enterprise Value Multiple
16.45 10.62 12.03 4.33 18.68
Enterprise Value
100.50B 74.13B 80.47B 85.98B 122.21B
EV to EBITDA
16.45 10.62 12.03 4.33 18.68
EV to Sales
3.48 2.83 2.80 3.20 5.17
EV to Free Cash Flow
0.00 17.00 17.65 24.76 35.26
EV to Operating Cash Flow
0.00 12.22 12.84 16.02 22.95
Tangible Book Value Per Share
1.19 1.59 1.93 1.92 1.07
Shareholders’ Equity Per Share
0.96 1.30 1.60 1.61 0.89
Tax and Other Ratios
Effective Tax Rate
0.09 0.15 0.13 0.11 0.13
Revenue Per Share
0.87 1.12 1.55 1.43 1.26
Net Income Per Share
0.10 0.10 0.27 0.78 0.23
Tax Burden
0.66 0.43 0.87 0.79 0.87
Interest Burden
1.02 0.92 1.02 0.98 0.94
Research & Development to Revenue
0.18 0.17 0.15 0.14 0.11
SG&A to Revenue
0.07 0.07 0.08 0.08 0.11
Stock-Based Compensation to Revenue
<0.01 <0.01 <0.01 0.00 0.00
Income Quality
0.00 1.02 1.08 0.29 1.06
Currency in CNY
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis